Subscribe
republica
republica / iStockphoto.com
9 November 2017Big Pharma

Danish court invalidates Gilead SPC

The Danish Maritime and Commercial High Court has invalidated a supplementary protection certificate (SPC) owned by Gilead.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Kite and Gadeta team up in cancer fight
23 July 2018   Biopharmaceutical company Kite, a subsidiary of Gilead, and immunotherapy development company Gadeta announced on Thursday, July 19 that they have entered into a strategic collaboration to produce cancer therapies.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Kite and Gadeta team up in cancer fight
23 July 2018   Biopharmaceutical company Kite, a subsidiary of Gilead, and immunotherapy development company Gadeta announced on Thursday, July 19 that they have entered into a strategic collaboration to produce cancer therapies.

More on this story

Americas
Kite and Gadeta team up in cancer fight
23 July 2018   Biopharmaceutical company Kite, a subsidiary of Gilead, and immunotherapy development company Gadeta announced on Thursday, July 19 that they have entered into a strategic collaboration to produce cancer therapies.

More features

GSK triumphs in EPO appeal, revoking Pfizer patent
‘We took Ravgen head-on’: How we won zero-damages and others didn't
Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks
Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch